Engineering and characterization of a single-chain antibody fragment (scFV1924) against the human sarcoma-associated antigen p102.
BACKGROUND
Monoclonal Antibody (MAb) 19-24 against the human sarcoma-associated antigen (SAA) p102 was previously characterized, and it demonstrated potential for sarcoma immunodiagnosis and immunotherapy. Due to the limitations of using intact murine MAbs in human clinical settings, we engineered a single-chain antibody fragment of MAb 19-24 (scFV1924).


METHODS
Monoclonal Antibody (MAb) 19-24 against the human sarcoma-associated antigen (SAA) p102 was previously characterized, and it demonstrated potential for sarcoma immunodiagnosis and immunotherapy. Due to the limitations of using intact murine MAbs in human clinical settings, we engineered a single-chain antibody fragment of MAb 19-24 (scFV1924).


RESULTS
The results from competition radioimmunoassay showed that binding of MAb 19-24 to SAA p102 on sarcoma cell membranes was inhibited by scFV1924.


CONCLUSIONS
This indicates the potential of further application of the scFV1924 in human sarcoma immunotherapy.
Chen
H
H
Department of Surgical Oncology, University of Illinois, Chicago College of Medicine, USA.
Wang
P
P
Das Gupta
T K
TK
D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000235:genetics* / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology; D001483:Base Sequence; D006801:Humans; D007128:Immunoglobulin Fragments / Q000235:genetics*; D008969:Molecular Sequence Data; D015202:Protein Engineering; D011863:Radioimmunoassay; D011994:Recombinant Proteins / Q000276:immunology; D012509:Sarcoma / Q000628:therapy; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007128:Immunoglobulin Fragments; D011994:Recombinant Proteins; C071921:antigen p102; C055966:immunoglobulin Fv